ELISpot and FluoroSpot Assay Market Research Report – Global Forecast till 2027

ELISpot and FluoroSpot Assay Market Research Report, by Product (Assay Kit, Ancillary Products), Application (Transplant, Vaccines), End-User (Hospitals and Clinics, Ambulatory Surgical Centres, Diagnostic Centres, Research Centers) – Forecast Till 2027

ID: MRFR/LS/5483-HCR | February 2021 | Region: Global | 90 pages

ELISpot and FluoroSpot Assay Market Scenario:


The ELISpot and FluoroSpot Assay Market were estimated USD 135 million in 2017 and expected to reach USD 287 million by 2023 at a CAGR of 16.2 % during the forecast period.


ELISpot and FluoroSpot Assay are a sensitive technique used for the recognition of immune cells which specific proteins such as cytokines or antibodies. These asses are used in hospitals and research institutes for early diagnosis for diseases such as TB and other viral infection. The FluoroSpot assay is a modification of ELISpot in which combinations of monoclonal antibodies with different reagents are used to detect the infection. The key factor responsible for driving the market growth are increasing incidence of chronic diseases, rising vaccine development to solve the challenge of antimicrobial resistance, technological advancements in analyzers and ELISpot and FluoroSpot assay kits. However, the factors such as lack of skilled technicians, and alternative detection technologies may limit the ELISpot and FluoroSpot Assay Market growth during the forecast period. 


Segmentation:


The ELISpot and FluoroSpot Assay Market is segmented on the basis of product, application, and end-user. The market, by product is categorised into various assay kit, analyzer, ancillary products. The assay kit is sub-segmented into T Cell assay and B Cell assay. On the basis of application, the market is segmented into transplant, vaccines development, clinical trials, cancer treatment. On the basis of end-user, the market is segmented into hospitals and clinics, ambulatory surgical centres, diagnostic centres, research centers, and others.


On the basis of region, the ELISpot and FluoroSpot Assay Market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is sub-segmented into North America and South America. The North American region is further segmented into the US and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the UK, Spain, and the rest of Western Europe. The Asia-Pacific region is sub-segmented into Japan, China, India, Australia, the Republic of Korea, and the rest of Asia-Pacific. The Middle Eastern and African region is sub-segmented into the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar, and the rest of the Middle East and Africa.


Key players:


Some of the key players in the ELISpot and FluoroSpot Assay Market are Oxford Immunotec (UK), Cellular Technologies (US), Mabtech (Sweden), Becton, Dickinson and Company (US), and Abcam (UK)Bio-Techne (US), Autoimmun Diagnostika (Germany), Biotech Investissement (France), Lophius Biosciences (Germany), and U-CyTech (Netherlands), and Others.


Regional Market Summary:


Global ELISpot and FluoroSpot Assay Market Share (%), by Region, 2017


Sources: National Cancer Institute, Cancer research UK, the American Cancer Society, Inc, US Department of Health and Human Services National Institutes of HealthIt is estimated that North America dominated the ELISpot and FluoroSpot Assay Market owing to the increasing cardiac diseases, innovations in clinical practice, increasing research and development in pharmaceutical industries boost the market growth. According to the Centers for Disease Control and Prevention 2017 publication 83.4% of children aged 19-35 months were vaccinated with Diphtheria, Tetanus, Pertussis in the US. The increasing demand for vaccines will boost the market growth.


Europe stood second largest in the ELISpot and FluoroSpot Assay market owing to the increasing number of pharmaceutical companies, rising in the development of innovative vaccines for the treatment of various viral diseases. The growing funding from government and private agencies for drug development also support the market in this region.  Asia-Pacific was estimated to be the fastest growing region for the Market in 2017. The market is expected to witness growth owing to the rising prevalence of viral infection, increasing geriatric population in this region and growing demand for ELISpot and FluoroSpot Assay in research field.


The Middle East and Africa holds the least share in the ELISpot and FluoroSpot Assay Market due to the presence of low health expenditure, lack of skilled technicians and less pharmaceutical company in this region. However, the market is expected to witness growth due to increasing research & development in the Middle East.


Market Segmentation and Key Market Players:


Market of ELISpot and FluoroSpot Assay, by Product:



  • Assay Kit


    •  T Cell assay

    • B Cell assay


  • Analyzer

  • Ancillary Products 


Market of ELISpot and FluoroSpot Assay, by Application:



  • Transplant,

  • Vaccines

  • Clinical Trials

  • Cancer Treatment


ELISpot and FluoroSpot Assay Market, by End-Users:



  • Hospitals and clinics

  • Ambulatory surgical centers

  • Diagnostic centers

  • Research centers

  • Others


ELISpot and FluoroSpot Assay Market, by Region:



  • Americas

  • Europe

  • Asia-Pacific

  • Middle East & Africa 


Intended Audience:



  • Pharmaceutical companies

  • Biotechnological institutes

  • Government and private laboratories

  • Research and Development (R&D) companies

  • Medical research laboratories

  • Market research and consulting service providers